D-penicillamine-induced mucocutaneous lesions with features of pemphigus.
Penicillamine (beta1 beta2 dimethylcysteine) is the drug of choice in the therapeutic management of Wilson's disease and cystinuria and has been used in the treatment of some heavy-metal intoxications. Recent studies have shown that it is efficacious in patients with rheumatoid arthritis. Side effects include sensitivity reactions, nephrotoxicity, bone-marrow suppression, hypogeusia, skin lesions, and the formation of autoantibodies. Two cases are described with the features of pemphigus which were attributed to penicillamine therapy.
D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D009061:Mouth Mucosa / Q000187:drug effects* / Q000276:immunology; D010392:Pemphigus / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D010396:Penicillamine / Q000009:adverse effects*
D010396:Penicillamine